Congress Materials

Medical Information
Ireland
 

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

This content is intended for U.S. Healthcare Professionals. Would you like to proceed?

I am a healthcare professionalYes, I am a healthcare professional
SelectI am a healthcare professionalYes, I am a healthcare professional
I am a Patient/Caregiver or
Member of the General PublicNo, go back to the patient portal
SelectI am a Patient/Caregiver or
Member of the General PublicNo, go back to the patient portal

If you don't reside in Ireland, please click here

The medical information on this site is intended only for healthcare professionals in the Republic of Ireland. The products discussed herein may have different product labeling in other countries.

This information is not intended as medical advice. Responsibility for patient care resides with the healthcare professional on the basis of his or her professional license, experience and knowledge of the patient.

Congress Materials

The information on this page pertains to select congresses, congress materials, therapeutic and disease areas. It is not intended to serve as a comprehensive overview of all congresses, congress materials, therapeutic and disease areas.
Congress materials may include information for which the product is not approved and/or inconsistent with the product uses described in the Prescribing Information. Pfizer does not suggest or recommend the use of Pfizer Products in any manner other than as described in the Prescribing Information.
Poster
Solit DB, Mettu NB, McCall SJ, Dhawan M, Bobbili PJ, DerSarkissian M, Ivanova J, Chang J, Niyazov A, Lee J, Huq R, Green M, Turski M, Muthukumar A, Guo T, Duh MS, Oh WK April 16, 2023 AACR 2023 Prostate Cancer

Treatment Patterns and Overall Survival Among Men With Metastatic Castration-Resistant Prostate Cancer Harboring HRR Mutations

View Presentation View Abstract Plain Language Summary
Poster
Crawford J, Calle RA, Collins SM, Weng Y, Lubaczewski SL, Buckeridge C, Wang EQ, Harrington MA, Tarachandani A, Rossulek MI, Revkin JH April 17, 2023 AACR 2023 Other/Multi-Tumor

First-In-Patient (Phase 1b) Study of the GDF-15 Inhibitor Ponsegromab in Participants With Cancer and Cachexia: Safety, Tolerability, and Exploratory Measures of Efficacy

View Presentation
Poster
Crawford J, Lubaczewski SL, Tarachandani A, Harrington MA, Weng Y, Qiu R, Collins SM, Rossulek MI, Revkin JH April 17, 2023 AACR 2023 Other/Multi-Tumor

Phase 2 Study to Assess the Efficacy, Safety, and Tolerability of the GDF-15 Inhibitor Ponsegromab in Patients With Cancer Cachexia

View Presentation
Poster
Schadendorf D, Dummer R, Robert C, Ribas A, Sullivan RJ, Panella T, McKean M, Santos ES, Clancy J, Polli A, di Pietro A, Ascierto PA April 17, 2023 AACR 2023 Skin Cancer

Randomized Phase 3 Study (STARBOARD) Evaluating Encorafenib (Enco) + Binimetinib (Bini) + Pembrolizumab (Pembro) for First-Line Treatment of Unresectable Locally Advanced or Metastatic BRAF V600-Mutant Melanoma

View Presentation View Abstract Plain Language Summary
Poster
Karam J, Rejto P, Bienkowska JR, Mu XJ, Roh W April 18, 2023 AACR 2023 Breast Cancer

Identification of Tumor-Specific Breast Cancer Expression Subtypes and Subtype-Specific Drug Response Prediction

View Presentation